Effect of interval between neoadjuvant chemoradiotherapy and surgery on disease recurrence and survival in rectal cancer: long-term results of a randomized clinical trial

Basit Öğe Kaydı
dc.authoridBozbiyik, Osman/0000-0002-1827-2720
dc.authorscopusid6603718068
dc.authorscopusid15128592000
dc.authorscopusid56028797100
dc.authorscopusid35622851900
dc.authorscopusid8901271400
dc.authorscopusid6602289001
dc.authorscopusid6701658370
dc.contributor.authorAkgun, Erhan
dc.contributor.authorCaliskan, Cemil
dc.contributor.authorBozbiyik, Osman
dc.contributor.authorYoldas, Tayfun
dc.contributor.authorDoganavsargil, Basak
dc.contributor.authorOzkok, Serdar
dc.contributor.authorKose, Timur
dc.date.accessioned2023-01-12T20:00:18Z
dc.date.available2023-01-12T20:00:18Z
dc.date.issued2022
dc.departmentN/A/Departmenten_US
dc.description.abstractBackground: The optimal timing of surgery following chemoradiotherapy (CRT) is controversial. This trial aimed to assess disease recurrence and survival rates between patients with locally advanced rectal adenocarcinoma (LARC) who underwent total mesorectal excision (TME) after a waiting interval of 8 weeks or less (classic interval; CI) versus more than 8 weeks (long interval; LI) following preoperative CRT. Methods: This was a phase III, single-centre, randomized clinical trial. Patients with LARC situated within 12 cm of the anal verge (T3-T4 or N+ disease) were randomized to undergo TME within or after 8 weeks after CRT. Results: Between January 2006 and January 2017, 350 patients were randomized, 175 to each group. As of February 2022, the median follow-up time was 80 (6-174) months. Among the 322 included patients (CI, 159; LI, 163) the cumulative incidence of locoregional recurrence at 5 years was 10.1 per cent in the CI group and 6.9 per cent in the LI group (P = 0.143). The cumulative incidence of distant metastasis at 5 years was 30.8 per cent in the CI group and 18.6 per cent in the LI group (sub-HR = 1.78; 95 per cent c.i. 1.14 to 2.78, P = 0.010). The disease-free survival (DFS) in each group was 59.7 and 69.9 per cent respectively (P = 0.157), and overall survival (OS) rates at 5 years were 73.6 versus 77.9 per cent (P = 0.476). Conclusion: Incidence of distant metastasis decreased with an interval between CRT and surgery exceeding 8 weeks, but this did not impact on DFS or OS.en_US
dc.identifier.doi10.1093/bjsopen/zrac107
dc.identifier.issn2474-9842
dc.identifier.issue5en_US
dc.identifier.pmid36254732en_US
dc.identifier.scopus2-s2.0-85140271528en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1093/bjsopen/zrac107
dc.identifier.urihttps://hdl.handle.net/11454/77316
dc.identifier.volume6en_US
dc.identifier.wosWOS:000869372900001en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherOxford Univ Pressen_US
dc.relation.ispartofBjs Openen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectPathological Complete Responseen_US
dc.subjectShort-Course Radiotherapyen_US
dc.subjectPreoperative Chemoradiotherapyen_US
dc.subjectTumor-Regressionen_US
dc.subjectLocal Recurrenceen_US
dc.subjectPrognostic Valueen_US
dc.subjectLymph-Nodesen_US
dc.subjectChemoradiationen_US
dc.subjectTherapyen_US
dc.subjectMulticenteren_US
dc.titleEffect of interval between neoadjuvant chemoradiotherapy and surgery on disease recurrence and survival in rectal cancer: long-term results of a randomized clinical trialen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu